Why Is RHYTHM PHARMACEUTICA (RYTM) Stock Up Today?
By the Top Tier Newswire AI Desk · November 17, 2026 at 12:13 PM ET · reviewed against 3 wire stories
RHYTHM PHARMACEUTICA (RYTM) is up +5.87% in the latest session. Our newswire has captured 3 stories on RYTM across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 67/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Rhythm Pharmaceuticals (RYTM) shares rose 5.87% to $113.79 as the company presented new clinical data for its obesity drug. The primary driver was the release of two-year results from the Phase 3 TRANSCEND trial, which demonstrated that continuous setmelanotide therapy sustained BMI reductions in patients with acquired hypothalamic obesity.
What Happened
Rhythm Pharmaceuticals announced the presentation of new data at ObesityWeek 2026. The two-year results from the Phase 3 TRANSCEND trial showed that continuous setmelanotide therapy sustained BMI reductions in patients with acquired hypothalamic obesity. This clinical update follows recent reports regarding a proposed $10 billion acquisition by AstraZeneca. Additionally, the National Institute for Health and Care Research (NICE) issued positive guidance for IMCIVREE in adults with Bardet-Biedl Syndrome. The company has been unprofitable, with trailing twelve-month earnings per share of negative $2.91, but revenue grew 61.0% over the same period.
What The Data Shows
The stock opened at $104.00, a 3.2% gap down from the prior close of $107.48. It reached a session high of $117.00 at 11:55 AM ET and a session low of $104.00 at 7:15 AM ET. Volume stood at 0.9 million shares, which is 1.0 times the three-month daily average. The company has a market capitalization of $8.0 billion and a beta of 2.14. The 52-week range is $74.50 to $122.20. Over the last 8 sessions, the stock moved up 2.3% from $105.02 to $107.48. Recent insider activity includes two sales totaling $11.8 million in the last 90 days, with the most recent sale by President and CEO David P. Meeker on September 14, 2026.
What To Watch
Investors will monitor the market reaction to the new clinical data and the ongoing acquisition discussions. The stock has printed 8 fresh 52-week highs and 11 fresh 52-week lows recently, indicating high volatility.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026
– Two-year results from Phase 3 TRANSCEND trial showed continuous setmelanotide therapy sustained BMI reductions in patients with acquired hypothalamic obesity –
3d agoBusiness InsiderBULLISH 63Product/PR
Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026
– Two-year results from Phase 3 TRANSCEND trial showed continuous setmelanotide therapy sustained BMI reductions in patients with acquired hypothalamic obesity –
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →